Concepedia

Yakub Kadernani

YK

3

Publications

63

Citations

3

H-Index

2014

Active since

Affiliations

The Francis Crick Institute(Current)

National Institute of Allergy and Infectious Diseases

Imperial College London

Wellcome Centre for Infectious Diseases Research in Africa

Somerset Hospital

Yakub Kadernani is an author at The Francis Crick Institute specializing in drug discovery, medicinal chemistry, and neurophysiology.

ORCID

Top concepts

Publications per year

2014–2022

3

Publications

3

A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus–Associated Tuberculous Meningitis: The LASER-TBM Trial

Angharad Davis, Sean Wasserman, Cari Stek et al. · Clinical Infectious Diseases · 2022 · 37 citations · Full text

Adamantane amine derivatives as dual acting NMDA receptor and voltage-gated calcium channel inhibitors for neuroprotection

Yakub Kadernani, Frank T. Zindo, Erika Kapp et al. · MedChemComm · 2014 · 14 citations

, , +17

Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM]

Angharad Davis, Sean Wasserman, Mpumi Maxebengula et al. · Wellcome Open Research · 2021 · 12 citations · Full text

Rows per page

1–3 of 3